ArticleBulletin of experimental biology and medicine2025
Diagnostic and Prognostic Significance of RASSF8-AS1 lncRNA Expression in Non-Small Cell Lung Cancer.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical significance of the long non-coding RNA (lncRNA) RASSF8-AS1 was investigated in non-small cell lung cancer (NSCLC). A comparative analysis of RASSF8-AS1 expression levels was performed in 31 paired samples of tumor tissue and adjacent morphologically normal lung tissue obtained from patients with various histological subtypes of NSCLC. Significant downregulation of RASSF8-AS1 transcript levels was observed in both lung adenocarcinoma (p = 0.0094) and squamous cell carcinoma (p = 0.0005). These findings underscore the potential of RASSF8-AS1 as a molecular marker for distinguishing histological subtypes of NSCLC. Although no significant associations were found between RASSF8-AS1 expression and patient age, tumor stage, or differentiation grade, a statistically significant correlation was identified between high RASSF8-AS1 expression and reduced overall survival specifically in patients with lung adenocarcinoma (hazard ratio, HR = 6.063; p = 0.029). This suggests that lncRNA RASSF8-AS1 may serve as a potential prognostic biomarker in this subgroup. Collectively, the results indicate a possible role for RASSF8-AS1 in NSCLC pathogenesis and support its further evaluation as both a molecular target and a prognostic tool, particularly in the context of personalized therapeutic strategies for lung adenocarcinoma.
Indexed as
Identifiers
41663841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.